Lower CagriSema Doses Beat Placebo; Early Response Matters
Summary
Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.
Description from Medscape.
Who is covering this
-
Lower CagriSema Doses Beat Placebo; Early Response Matters
Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.
Comments
Comments need JavaScript.